Bayforest Capital Ltd Buys 5,067 Shares of Insmed, Inc. $INSM

Key Points

• Bayforest Capital Ltd increased its stake in Insmed, Inc. by 255.0%, owning 7,054 shares valued at approximately $538,000.
• Insmed reported a loss of $1.70 EPS for the last quarter, missing estimates, but had an annual revenue increase of 18.9%.
• Several analysts have raised their price targets for Insmed, with an average target of $139.86 and a rating of "Moderate Buy."

Bayforest Capital Ltd boosted its position in Insmed, Inc. (NASDAQ:INSM - Free Report) by 255.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,054 shares of the biopharmaceutical company's stock after purchasing an additional 5,067 shares during the period. Bayforest Capital Ltd's holdings in Insmed were worth $538,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in INSM. M&T Bank Corp lifted its position in shares of Insmed by 4.7% during the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock valued at $252,000 after acquiring an additional 147 shares during the last quarter. Snowden Capital Advisors LLC lifted its position in shares of Insmed by 2.5% during the 4th quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock valued at $456,000 after acquiring an additional 158 shares during the last quarter. Cullen Frost Bankers Inc. lifted its position in shares of Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 221 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Insmed by 6.5% during the 1st quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company's stock valued at $287,000 after acquiring an additional 228 shares during the last quarter. Finally, Parkman Healthcare Partners LLC lifted its position in shares of Insmed by 0.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 35,668 shares of the biopharmaceutical company's stock valued at $2,463,000 after acquiring an additional 235 shares during the last quarter.

Insmed Stock Up 0.1%

Insmed stock traded up $0.14 during mid-day trading on Friday, hitting $145.93. 1,926,423 shares of the company's stock were exchanged, compared to its average volume of 2,206,758. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $149.08. The stock has a 50 day moving average of $119.40 and a two-hundred day moving average of $91.91. The stock has a market cap of $30.85 billion, a P/E ratio of -25.56 and a beta of 0.97.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. During the same quarter last year, the company earned ($1.94) earnings per share. The firm's revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Activity at Insmed

In related news, CFO Sara Bonstein sold 58,400 shares of the stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $102.67, for a total value of $5,995,928.00. Following the completion of the sale, the chief financial officer owned 73,505 shares in the company, valued at approximately $7,546,758.35. This trade represents a 44.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $129.50, for a total transaction of $1,295,000.00. Following the completion of the sale, the director owned 274,516 shares of the company's stock, valued at approximately $35,549,822. The trade was a 3.51% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 378,382 shares of company stock valued at $40,169,038. 3.00% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on INSM. Truist Financial increased their price objective on Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Royal Bank Of Canada upped their price target on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Morgan Stanley increased their target price on shares of Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 21st. Citigroup raised shares of Insmed to a "buy" rating in a research report on Tuesday, June 10th. Finally, Bank of America increased their target price on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. Sixteen equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $139.86.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.